Kyverna Therapeutics (KYTX) News Today → This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad) Free KYTX Stock Alerts $15.42 +0.17 (+1.11%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 18 at 1:47 AM | americanbankingnews.comKyverna Therapeutics, Inc. to Post Q2 2024 Earnings of ($0.69) Per Share, Leerink Partnrs Forecasts (NASDAQ:KYTX)May 17 at 7:10 AM | marketbeat.comKyverna Therapeutics, Inc. Expected to Post Q2 2024 Earnings of ($0.69) Per Share (NASDAQ:KYTX)Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Research analysts at Leerink Partnrs reduced their Q2 2024 earnings per share (EPS) estimates for Kyverna Therapeutics in a report released on Tuesday, May 14th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnMay 16 at 11:05 AM | markets.businessinsider.comBuy Rating for Kyverna Therapeutics Based on KYV-101’s Clinical Progress and Financial StabilityMay 16 at 11:05 AM | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics Amidst Positive Clinical Trials and Manufacturing AdvancementsMay 15 at 7:02 PM | msn.comKyverna Therapeutics reports Q1 GAAP EPS of -$1.12May 15 at 5:39 PM | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Trading 11.4% Higher Kyverna Therapeutics (NASDAQ:KYTX) Trading Up 11.4%May 15 at 4:47 PM | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Announces Earnings ResultsKyverna Therapeutics (NASDAQ:KYTX - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.28). During the same quarter in the previous year, the company earned ($12.10) EPS.May 15 at 12:06 AM | investorplace.comKYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024May 14, 2024 | prnewswire.comKyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 13, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up to $14.00Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up to $14.00May 11, 2024 | americanbankingnews.comComparing Kyverna Therapeutics (NASDAQ:KYTX) & Sana Biotechnology (NASDAQ:SANA)May 9, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Shares Up 8.7%Kyverna Therapeutics (NASDAQ:KYTX) Shares Up 8.7%May 8, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Stock Price Down 8.9%Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 8.9%May 8, 2024 | americanbankingnews.comC4 Therapeutics (NASDAQ:CCCC) vs. Kyverna Therapeutics (NASDAQ:KYTX) Financial ContrastMay 6, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Reaches New 12-Month Low at $13.89Kyverna Therapeutics (NASDAQ:KYTX) Reaches New 12-Month Low at $13.89May 2, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Shares Down 7.3% Kyverna Therapeutics (NASDAQ:KYTX) Shares Down 7.3%April 30, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Trading 4.5% Higher Kyverna Therapeutics (NASDAQ:KYTX) Shares Up 4.5%April 25, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Trading Down 6.6%Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 6.6%April 24, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Sets New 52-Week Low at $17.70Kyverna Therapeutics (NASDAQ:KYTX) Hits New 52-Week Low at $17.70April 22, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Stock Price Up 6.4%Kyverna Therapeutics (NASDAQ:KYTX) Shares Up 6.4%April 19, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Shares Down 2.8% Kyverna Therapeutics (NASDAQ:KYTX) Trading Down 2.8%April 18, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Sees Unusually-High Trading VolumeKyverna Therapeutics (NASDAQ:KYTX) Sees Strong Trading VolumeApril 17, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Hits New 52-Week Low at $21.13Kyverna Therapeutics (NASDAQ:KYTX) Hits New 52-Week Low at $21.13April 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Drug Efficacy and Safety DataApril 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics on Promising KYV-101 Clinical AdvancesApril 11, 2024 | finance.yahoo.comKyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesApril 11, 2024 | prnewswire.comKyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune DiseasesApril 8, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Trading Up 5.1%Kyverna Therapeutics (NASDAQ:KYTX) Trading 5.1% HigherApril 3, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Hits New 12-Month Low at $21.71Kyverna Therapeutics (NASDAQ:KYTX) Sets New 52-Week Low at $21.71April 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kyverna Therapeutics on Promising Early-Stage KYV-101 Results for MS TreatmentApril 2, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Shares Up 4.6%Kyverna Therapeutics (NASDAQ:KYTX) Trading 4.6% HigherMarch 29, 2024 | finance.yahoo.comFirst-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedMarch 29, 2024 | prnewswire.comFirst-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in MedMarch 29, 2024 | markets.businessinsider.comBuy Recommendation: Kyverna Therapeutics’ Innovative Autoimmune Cell Therapy and Robust Pipeline Promise Market LeadershipMarch 29, 2024 | marketbeat.comLeerink Partnrs Comments on Kyverna Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:KYTX)Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Investment analysts at Leerink Partnrs decreased their Q1 2024 earnings per share estimates for shares of Kyverna Therapeutics in a report issued on Wednesday, March 27th. Leerink Partnrs analyst T. Smith now forecasts that the company willMarch 27, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Shares Down 3.5% Kyverna Therapeutics (NASDAQ:KYTX) Stock Price Down 3.5%March 27, 2024 | finance.yahoo.comKyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial ResultsMarch 25, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Reaches New 12-Month Low at $25.09Kyverna Therapeutics (NASDAQ:KYTX) Hits New 1-Year Low at $25.09March 21, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Stock Price Up 6.7%Kyverna Therapeutics (NASDAQ:KYTX) Trading Up 6.7%March 19, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Hits New 1-Year Low at $25.78Kyverna Therapeutics (NASDAQ:KYTX) Reaches New 1-Year Low at $25.78March 18, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Trading Down 7.7%Kyverna Therapeutics (NASDAQ:KYTX) Stock Price Down 7.7%March 14, 2024 | finance.yahoo.comWhy That Hot Biotech IPO Could Be a WinnerMarch 7, 2024 | markets.businessinsider.comKyverna, Stanford University To Evaluate KYV-101 In Non-Relapsing & Progressive Forms Of MSMarch 7, 2024 | finance.yahoo.comHow Kyverna is positioned for success on autoimmune therapy: CEOMarch 6, 2024 | marketbeat.comEquities Analysts Offer Predictions for Kyverna Therapeutics, Inc.'s FY2023 Earnings (NASDAQ:KYTX)Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Research analysts at Leerink Partnrs issued their FY2023 EPS estimates for Kyverna Therapeutics in a research report issued on Monday, March 4th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings per share of ($March 6, 2024 | marketbeat.comLeerink Partnrs Reiterates "Outperform" Rating for Kyverna Therapeutics (NASDAQ:KYTX)Leerink Partnrs reaffirmed an "outperform" rating on shares of Kyverna Therapeutics in a research note on Monday.March 5, 2024 | marketbeat.comKyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up to $27.70Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up to $27.70March 4, 2024 | marketbeat.comSVB Leerink Initiates Coverage on Kyverna Therapeutics (NASDAQ:KYTX)SVB Leerink initiated coverage on shares of Kyverna Therapeutics in a report on Monday. They set an "outperform" rating and a $48.00 price objective on the stock.February 27, 2024 | morningstar.comKyverna Therapeutics Inc KYTXFebruary 27, 2024 | investing.comKyverna Therapeutics Inc (KYTX) Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Automatic Income (from home) (Ad)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part… Watch this short video KYTX Media Mentions By Week KYTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KYTX News Sentiment▼0.020.50▲Average Medical News Sentiment KYTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KYTX Articles This Week▼125▲KYTX Articles Average Week Get Kyverna Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ITOS News EXAI News VALN News CABA News HLVX News TSHA News ADPT News HUMA News ALEC News RGNX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KYTX) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceA once-in-a-century investment opportunityStansberry Research[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
